Of the many approved DMT for MS and RA, teriflunomide/leflunomide and anti-CD20 therapies represent the most suitable treatment options for people with moderately or highly active MS, respectively, and comorbid RA. The gene discussed is MS4A1; the disease is rheumatoid arthritis.